🚀 VC round data is live in beta, check it out!
GRAIL Valuation Multiples
Discover revenue and EBITDA valuation multiples for GRAIL and similar public comparables like GeneDx, Genus, Fleury, BGI Genomics and more.
GRAIL Overview
About GRAIL
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Founded
2015
HQ
Employees
1.0K
Website
Financials (LTM)
EV
$1B
GRAIL Financials
GRAIL reported last 12-month revenue of $157M and negative EBITDA of ($379M).
In the same LTM period, GRAIL generated ($6M) in gross profit, ($379M) in EBITDA losses, and had net loss of ($428M).
Revenue (LTM)
GRAIL P&L
In the most recent fiscal year, GRAIL reported revenue of $147M and EBITDA of ($378M).
GRAIL expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $157M | XXX | $147M | XXX | XXX | XXX |
| Gross Profit | ($6M) | XXX | ($63M) | XXX | XXX | XXX |
| Gross Margin | (4%) | XXX | (43%) | XXX | XXX | XXX |
| EBITDA | ($379M) | XXX | ($378M) | XXX | XXX | XXX |
| EBITDA Margin | (241%) | XXX | (257%) | XXX | XXX | XXX |
| EBIT Margin | (305%) | XXX | (330%) | XXX | XXX | XXX |
| Net Profit | ($428M) | XXX | ($408M) | XXX | XXX | XXX |
| Net Margin | (272%) | XXX | (277%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
GRAIL Stock Performance
GRAIL has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
GRAIL's stock price is $51.71.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | 0.0% | XXX | XXX | XXX | $-9.95 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGRAIL Valuation Multiples
GRAIL trades at 8.1x EV/Revenue multiple, and (3.4x) EV/EBITDA.
EV / Revenue (LTM)
GRAIL Financial Valuation Multiples
As of April 19, 2026, GRAIL has market cap of $2B and EV of $1B.
Equity research analysts estimate GRAIL's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GRAIL has a P/E ratio of (5.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 8.1x | XXX | 8.6x | XXX | XXX | XXX |
| EV/EBITDA | (3.4x) | XXX | (3.4x) | XXX | XXX | XXX |
| EV/EBIT | (2.7x) | XXX | (2.6x) | XXX | XXX | XXX |
| EV/Gross Profit | (211.0x) | XXX | (20.3x) | XXX | XXX | XXX |
| P/E | (5.0x) | XXX | (5.2x) | XXX | XXX | XXX |
| EV/FCF | (4.3x) | XXX | (4.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified GRAIL Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
GRAIL Margins & Growth Rates
GRAIL's revenue in the last 12 month grew by 23%.
GRAIL's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.5M for the same period.
GRAIL's rule of 40 is (177%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GRAIL's rule of X is (143%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
GRAIL Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Margin | (241%) | XXX | (257%) | XXX | XXX | XXX |
| EBITDA Growth | (6%) | XXX | (5%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (177%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (143%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 78% | XXX | 80% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 104% | XXX | 113% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 124% | XXX | 134% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 320% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
GRAIL Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics and Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| GRAIL | XXX | XXX | XXX | XXX | XXX | XXX |
| GeneDx | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| Fleury | XXX | XXX | XXX | XXX | XXX | XXX |
| BGI Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| SonoScape | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GRAIL M&A Activity
GRAIL acquired XXX companies to date.
Last acquisition by GRAIL was on XXXXXXXX, XXXXX. GRAIL acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by GRAIL
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGRAIL Investment Activity
GRAIL invested in XXX companies to date.
GRAIL made its latest investment on XXXXXXXX, XXXXX. GRAIL invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by GRAIL
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout GRAIL
| When was GRAIL founded? | GRAIL was founded in 2015. |
| Where is GRAIL headquartered? | GRAIL is headquartered in United States. |
| How many employees does GRAIL have? | As of today, GRAIL has over 1K employees. |
| Who is the CEO of GRAIL? | GRAIL's CEO is Robert Ragusa. |
| Is GRAIL publicly listed? | Yes, GRAIL is a public company listed on Nasdaq. |
| What is the stock symbol of GRAIL? | GRAIL trades under GRAL ticker. |
| When did GRAIL go public? | GRAIL went public in 2024. |
| Who are competitors of GRAIL? | GRAIL main competitors are GeneDx, Genus, Fleury, BGI Genomics. |
| What is the current market cap of GRAIL? | GRAIL's current market cap is $2B. |
| What is the current revenue of GRAIL? | GRAIL's last 12 months revenue is $157M. |
| What is the current revenue growth of GRAIL? | GRAIL revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of GRAIL? | Current revenue multiple of GRAIL is 8.1x. |
| Is GRAIL profitable? | No, GRAIL is not profitable. |
| What is the current EBITDA of GRAIL? | GRAIL has negative EBITDA and is not profitable. |
| What is GRAIL's EBITDA margin? | GRAIL's last 12 months EBITDA margin is (241%). |
| What is the current EV/EBITDA multiple of GRAIL? | Current EBITDA multiple of GRAIL is (3.4x). |
| What is the current FCF of GRAIL? | GRAIL's last 12 months FCF is ($293M). |
| What is GRAIL's FCF margin? | GRAIL's last 12 months FCF margin is (186%). |
| What is the current EV/FCF multiple of GRAIL? | Current FCF multiple of GRAIL is (4.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.